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Systemic lupus erythematosus (SLE), an autoimmune systemic disease with 
unknown etiology, affects virtually every part of the body; involvement of 
the central nervous system (CNS) is one of the major causes of morbidity 
and mortality in systemic lupus erythematosus (SLE) patients and is the least 
understood aspect of the disease. neutropenia is very uncommon in childhood 
lupus. True negative anti nuclear antibody (ANA) tests in patients with lupus 
are now very rare. The patient reported here was a 12-year-old girl with ANA 
negative lupus cerebritis who presented with left hemiparesia after a generalized 
seizure, with neutropenia observed during its course.
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Introduction
Systemic lupus erythematosus (SLE), an autoimmune disease involving multiple 
organ systems,has been defined clinically and is associated with antibodies directed 
against cell nuclei. Its multisystem manifestations and complications induced by 
use of immunosuppressive agents make the diagnosis and management of this 
disorder challenging (1). 
Childhood-onset SLE is often reported as being more severe than adult-onset 
disease. In a published series, a large proportion of both children and adolescents 
with SLE have been reported with significant renal or central nervous system (CNS) 
involvement (2). The spectrum of CNS manifestations varies widely, from those with 
severe, life-threatening presentations, such as transverse myelitis or stroke, to those 
with more subtle and subclinical abnormalities in neurocognitive function, such as 
memory, intellect and learning. The different pathogenic mechanisms involved are 
poorly understood and the therapy available is often disappointing (3). Leukopenia 
also occurs in up to 50% of patients with systemic lupus erythematosus (SLE) at 
some point during the course of the disease (4), but neutropenia (<1000neutrophils/
mm3) is very uncommon in childhood lupus (5).
Antinuclear antibody (ANA), an antibody to nucleosomal DNA-histone complexes, 
is present in over 90% of children and adolescents with SLE (2). True negative 
ANA test in patients with lupus are now very rare, perhaps 2% of sera at most (6).
We report here a case of lupus cerebritis who presented with left hemiparesia after a 
generalized seizure; this case deserved reporting, because in addition to an unusual 
clinical presentation, she had also uncommon paraclinical signs such as neutropenia 
and negative ANA tests.
CASE REPORT
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Case Report
The patient was a 12-year-old child was admitted 
due to lethargy and hemiparesia. Her illness began 
suddenly with a generalized tonic-clonic seizure, 
lasting about an hour (status epilepticus), following 
which left hemiparesia and lethargy occurred; she had 
3-year history of idiopathic epilepsy (Complex Partial 
Seizure), that had been controlled by carbamazepine 
and sodium valproate. 
At admission she was lethargic and asthenic with a 
low-grade fever and normal blood pressure. She had 
bilateral conjunctivitis and an ulcerated papule at 
mucocutaneous junction of nasal septum. Bilateral 
pulmonary fine crackles were present. Cardiac and 
abdominal examination was normal. There were few 
ecchymotic lesions on the lower limbs and an upward 
left plantar reflex.
A complete workup for infections was done except 
for lumbar puncture (her parents did not consent); 
broad-spectrum antibiotics and acyclovir were started. 
Phenytoin was prescribed for seizure control due to 
patient’s low level of consciousness and focal pattern 
of seizures.
Axial brain CT-scan was normal. Her brain MRI showed 
diffuse right hemispheral abnormal signals at T2W 
(figure 1). Electroencephalography showed diffuse theta 
(θ) waves that were compatible to diffuse parenchymal 
lesions. In echocardiography only there was a mild 
tricuspid regurgitation without any vegetation. 
Laboratory values in first few days were significant 
for WBC=5000cells/μl (Neutrophil=88), HCT=43% 
(MCV=83), PLT=112000/ μl, Reticulocyte count=0.3%. 
Urea=80mg/dL, Creatinine (Cr) =1 mg/dL, Na+=135 
mEq/L, K+=4 mEq/L, Blood Sugar=84 mg/dL, PT=20.2 
sec (control of 13 seconds) (INR=2.2),aPTT=35 
sec(control of 26 to 36 seconds), ABG was normal. ESR 
was 30mm/1h and CRP was positive. Liver function tests 
were abnormal (SGOT=134 (15-46 U/L), SGPT=57(8-
36 U/L), ALP=179U/L). Wright, Widal and PPD tests 
all were negative. The anti nuclear antibody (ANA) 
was also negative. Two blood cultures performed were 
negative after 48 hours.
On the third day of hospitalization (DOH), the patient’s 
renal function worsened (Urea=134 mg/dL, Cr=3 mg/
dL). Urine analysis showed a mild hematuria (WBC=1-
2, RBC=6-7, SG=1010). Urine culture was negative. 
Renal ultrasonography showed normal sized kidneys, 
but their parenchymal echogenicity was increased.
On the 8th DOH, fever with diffuse purpura and petechia 
on lower limbs, buttocks and trunk appeared, some being 
palpable purpuras. She complained from left upper and 
left lower limb pain. Color Doppler ultrasonography of 
limb vessels was normal; the following day she became 
ill and toxic. Edema and limb pain was accentuated. 
Other positive clinical signs were a moderate fever, 
bilateral pulmonary fine crackles, facial plethora which 
was more prominent in cheeks, significant lip edema 
and a painful edema in her left leg that was compatible 
with a deep vein thrombosis. One pulse of methyl 
prednisolone was administered with clinical diagnosis 
of SLE followed by oral prednisolone after 48 hours. 
Before corticosteroid administration, serologic tests 
for connective tissue disorders were controlled. The 
results were C3=100 (normal range 83 to 177mg/dL), 
C4=37(normal range 15 to 45mg/dL), ANA=6 u/ml 
(normal<10), ANCA was negative, anti ds-DNA=64 u/
ml (normal<27) ESR=118 mm/1h, Rheumatoid factor 
was negative and CPK=17U/L.
After steroid infusion, fever, facial plethora, malar rash 
and lip edema disappeared. Her coughs, pain, edema 
and petechia in the extremities decreased significantly 
after 24 hours, and respiratory symptoms and signs also 
improved. PT and PTT were normal. Renal function 
tests improved (Urea=29 mg/dL, Cr=0.8 mg/dL). Liver 
function was still abnormal (AST=92U/L, ALT=96U/
L). 
On the 19th DOH, neutropenia appeared (WBC=1700/μl 
(Neutrophil=24%, Lymphocyte=68%, Monocyte=8%)). 
Carbamazepine was discontinued. Because of poor seizure 
control, Primidone was added to sodium valproate. Bone 
marrow aspiration reported hypocellular without other 
abnormalities. Due to accentuation of neutropenia in the 
following days, granulocyte colony-stimulating factor 
(G-CSF) was started for two consecutive days. On the 
30th DOH, her general condition was very good and vital 
signs were stable. Her CBC returned to normal and she 
was discharged with outpatient follow up; at discharge 
her laboratory tests were as follows: WBC=10200/
μl (Neutrophil=64, Monocyte=8.8, Eosinophil=0.1), 
Hb=12.8 g/L, PLT=336000/μl, AST=62U/L, ALT=43U/
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L, ESR=25mm/h ,U/A (SG=1017, protein++, blood+, 
WBC=4-5/hpf, RBC=9-10/hpf, PH=6, CAST= negative), 
C3=100 mg/dL, C4=40 mg/dL, Anti Phospholipid 
Antibody (IgG) =1 (<10 U/mL). ANA was checked that 
was negative again. 
One month after discharge she had improved 
significantly and laboratory data were stable except for 
hematuria and mild proteinuria. According to active 
urine, azathiopurin was started for her. At present her 
disease is controlled completely. Her anti-ds DNA level 
and CBC are within normal ranges now. 
 
Figure 1: Brain MRI of patient showing diffuse right hemispheral abnormal signals at T2W imaging.
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Discussion
This is the rare documented case of cerebritis and 
neutropenia in a child with ANA negative Systemic 
Lupus Erythematosus.
Based on leucopenia, positive anti-ds DNA and 
neurologic manifestations, our patient had only 3 criteria 
according to the American College of Rheumatology 
(ACR) criteria for Diagnosis of SLE (7); hence she 
can be classified as probable SLE. We know that Anti-
dsDNA is virtually 100% (96-100) specific for SLE (it 
is ONLY positive in pts with SLE) (8). Rapid response 
to corticotherapy, and renal involvement (appearance of 
proteinuria) in follow up confirmed this diagnosis. 
Neurologic complications of systemic lupus cerebritis 
are not as well known in children as in adults (9). Stroke 
syndromes secondary to Neuropsychiatric-SLE (NP-
SLE) can affect any area of the brain. Strokes usually 
occur within the first 5 years of the onset of SLE. 
Cerbrovascular accidents occur in 5-15% of all SLE 
patients (10). Parikh and colleagues noted neurologic 
abnormalities in 25 of 108 (23 percent) of a series of 
patients with onset of SLE before the age of 20 years. 
Cerebrovascular accidents with hemiplegia or diplegia 
occurred in 7 of 25 and generalized tonic clonic seizures 
in 5 (9). In a study by Steinlin and coworkers, CNS 
abnormalities were noted in 40 of 91 patients, with 
onset of SLE before 18 years of age. Seizures occurred 
in 8 patients and were followed by a cerebrovascular 
accident in 2(11). In a recent study, twenty-five children 
with neurologic complications were identified after 
reviewing the hospital medical records of 86 children 
with systemic lupus erythematosus. Seven children 
(28%) had neurologic symptoms at the time of initial 
diagnosis of systemic lupus erythematosus, sixteen 
children had seizures, and 12 children had seizures 
as the initial central nervous system involvement. 
Five children had diffuse lupus cerebritis, three had 
stroke, and two had isolated cranial neuropathies (12). 
According to the history of onset of epilepsy in our 
patient during her school age period we can suppose 
that this epilepsy may be secondary to SLE. 
Severe CNS disease may present as a focal 
manifestation, usually thrombotic in nature, or as a 
diffuse manifestation, consequent to various pathogenic 
mechanisms, such as vasculitis, antibody mediated 
injury, multifocal thrombosis or a combination of 
these. However, precise attribution to one particular 
mechanism is not always easy and in some cases, as in 
our patient, focal (unilateral involvement in MRI) and 
diffuse manifestations (generalized teta waves in EEG) 
may coincide in the same patient (3).
The exact pathophysiological process of lupus cerebritis 
is unknown. The proposed mechanisms are likely due to 
the assault of several immune system changes, including 
the following: 
1. Circulating immune complexes: The immune 
complexes, which consist of DNA and anti-
DNA, cause an inflammatory response as well 
as a disruption of the blood-brain barrier. As 
mentioned anti ds-DNA was positive in our 
case.
2. Anti-neuronal antibodies: The three identified 
anti-neuronal antibodies postulated in CNS 
involvement are lymphocytotoxic antibodies 
(LCAs), which somehow react with brain tissue 
and interfere with the neuron’s ability to respond. 
the anti-neuronal membrane antibodies that 
are targeted directly to neuronal antigens, and 
the third, the intracytoplasmic antibodies that 
target the constituents of the neuron cells (i.e., 
ribosomes and neurofilaments). They are also 
called anti-SSA or anti-SSB antibodies, seen 
in 90% of SLE patients with psychosis. These 
antibodies were not checked in our patient.
3. Antiphospholipid antibodies: The lupus 
anticoagulant antibody prolongs coagulation. 
Stroke-like disorders, such as pulmonary emboli, 
thrombocytopenia, and arterial/venous thrombi, 
are seen in 30%–50% of SLE patients. In our 
patient antiphospholipid antibody was negative, 
two weeks after steroid therapy.
4. Cytokine release: The cytokines trigger edema, 
endothelial thickening, and infiltration of 
neutrophils in brain tissue (13). 
Suppression of the hematopoietic system, especially of 
the myeloid lineage, is a severe complication of systemic 
lupus erythematosus (SLE) (14). In a recent report 
Euler et al suggested G-CSF as an effective treatment 
of neutropenia during SLE (15). Our patient also had a 
rapid and significant response to Granulocyte colony-
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stimulating factor (G-CSF) administration.
The pathophysiology of neutropenia in SLE is complex 
and appears to involve both cellular and humoral immune 
mechanisms. Increased neutrophil margination and 
increased peripheral neutrophil destruction, possibly due 
to autoantibodies directed against polymorphonuclear 
neutrophils, may contribute to the development of 
neutropenia in some patients. In addition, suppression of 
neutrophil production and maturation by T lymphocytes 
(CD4+, CD8+, and CD57+) and autoantibodies against 
CD34+ hematopoietic progenitor cells has been 
demonstrated. If an immune-mediated pathogenesis is 
suspected, potential targets of immune injury are not 
only myeloid cells, but also mediators involved in the 
regulation of myelopoiesis. It has been demonstrated 
that cytokines and hematopoietic growth factors can 
indeed be the target of autoimmunity for autoimmune 
diseases as well for lymphoproliferative disorders (4).
The presence of lupus cerebritis and neutropenia in a 
patient may suggest a common mechanism. According 
to the above mentioned mechanisms for neutropenia and 
lupus cerebritis, one types of anti neuronal antibodies 
may contribute to both neuronal and neutrophil 
damage.
In our patient, ANA was reported negative three times 
during the first month of diagnosis. ANA negative 
patients with lupus usually fall into three categories: 1) 
anti phospholipid antibody syndrome, 2) early disease, 
and 3) previously positive ANA made negative by 
steroids, cytotoxic drugs, or uremia. Several reports 
have documented the delayed appearance of ANA in 
patients suspected of having SLE. Based on results 
of the Wallace group studies, documenting a mean of 
3 to 4 years between onset of symptoms and time of 
diagnosis, ANA negative SLE is not surprising (6). In 
our patient the most probable possibility may be the 
second category i.e. early disease.
Since 1945, many drugs have been reported as having the 
potential to cause lupus-like illness. The more notorious 
of these drugs, such as procainamide and hydralazine, 
are no longer in common use, but others such as 
anticonvulsants, isoniazid, and chlorpromazine are still 
widely prescribed. Differentiating drug-induced lupus 
from idiopathic lupus, or systemic lupus erythematosus 
(SLE), is important as it has greatly different prognostic 
and therapeutic implications. Fever, arthralgia, serositis 
and ANA occur at least as frequently in drug-induced 
disease as idiopathic SLE, hematological, renal and 
CNS involvement and ds-DNA are rare (16). Antibodies 
against double-stranded DNA (ds-DNA) are both 
sensitive and specific for active SLE in childhood but 
may occur in other conditions (2). According to positive 
ds-DNA and diffuse involvement of brain in EEG and 
MRI, drug induced lupus is less probable. Although 
drug induced disease can explain some symptoms and 
signs of our patient, but according to the persistence of 
renal problems in follow-up the diagnosis of SLE was 
confirmed. We must also consider that neutrpenia in this 
patient may be an adverse reaction of carbamazepine. But 
considering her normal neutrophil count at admission 
this possibility is less likely.
Liver function tests may be mildly elevated in acute 
SLE or in response to therapies such as azathioprine 
or nonsteroidal anti-inflammatory drugs (17). This 
patient also had a slight elevation in aminotransferses. 
The partial thromboplastin time (PTT) may be elevated 
secondary to lupus anticoagulant (antiphospholipid 
antibody), which is associated with thrombosis. In our 
patient the PTT was normal, while the prothrombin time 
(PT) was elevated; we have no specific explanation for 
this condition. It may be secondary to nutritional state 
of patient before admission or the mild hepatitis due to 
lupus. 
In summary it is important to consider lupus in 
differential diagnosis of childhood epilepsy and stroke-
like conditions. ANA is not necessarily positive in 
some patients at onset of SLE. Neutropenia in a patient 
with lupus cerebritis may suggest the presence of anti 
neuronal antibodies as the possible mechanism causing 
cerebritis.
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